"Long-Term Remission Under Combined, Systematic Therapy in Advanced or Metastatic Soft Tissue Sarcoma: A Case Report"

作者全名："Wang, Ping; Xia, Lei"

作者地址："[Wang, Ping; Xia, Lei] Chongqing Med Univ, Affiliated Hosp 2, Dept Canc Ctr, Chongqing 401336, Peoples R China; [Xia, Lei] Chinese Acad Med Sci & Peking Union Med Coll, Tianjin Key Lab Radiat Med & Mol Nucl Med, Inst Radiat Med, Tianjin 300110, Peoples R China; [Xia, Lei] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin 300060, Peoples R China"

通信作者："Xia, L (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Canc Ctr, Chongqing 401336, Peoples R China.; Xia, L (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Tianjin Key Lab Radiat Med & Mol Nucl Med, Inst Radiat Med, Tianjin 300110, Peoples R China.; Xia, L (通讯作者)，Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin 300060, Peoples R China."

来源：JOURNAL OF BIOMEDICAL NANOTECHNOLOGY

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:001094248400002

JCR分区：Q3

影响因子：2.9

年份：2023

卷号：19

期号：6

开始页：1098

结束页：1103

文献类型：Article

关键词：Soft Tissue Sarcoma; Anlotinib; PD-1 Inhibitor; Doxorubicin Liposome; Radiation Therapy

摘要："Soft tissue sarcomas (STSs) are rare and heterogeneous tumors with limited treatment options for advanced stages. In this case series, we present two patients with advanced STSs who were treated with a sequential maintenance therapy strategy of chemotherapy, anti-angiogenesis, PD-1 inhibitors, and local radiotherapy. The first patient had leiomyosarcoma, and the second patient had alveolar soft part sarcoma (ASPS). Both patients had negative PD-L1 results and high tumor mutation burden (TMB). The first patient progressed after multiline therapy and radiotherapy, while the second patient had advanced disease at diagnosis. The treatment regimen for both patients included doxorubicin and anlotinib, followed by maintenance therapy with anlotinib and tislelizumab. Both patients achieved long-term remission, with the second patient benefiting for 58 months. This systemic treatment approach offers a new option for personalized and precise treatment of advanced STSs. The success of this approach highlights the potential of combining chemotherapy, anti-angiogenesis, PD-1 inhibitors, and local radiotherapy for the treatment of advanced STSs."

基金机构：　

基金资助正文：